Biolase

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Marc2pk
Forum gebruiker
Forum gebruiker
Berichten: 106
Lid geworden op: 07 Nov 2012 16:23
Likes: 18
Contact:

Re: Biolase

Berichtdoor Marc2pk » 07 Mei 2014 14:22

Stefan,
Heb ze nog steeds in mijn bezit. Wel te hoog aangekocht.
Ze staan nu wel echt laag.
Sterk bedrijf, met een grote pipeline, maar heb mijn twijfels van de CEO.
Lijkt wel een ruziemaker. Biolase zit in proces met Oracle dat 16% van de aandelen bezit.


Stefan
Forum actieveling
Forum actieveling
Berichten: 475
Lid geworden op: 18 Dec 2012 18:52
Likes: 53
Contact:

Re: Biolase

Berichtdoor Stefan » 05 Okt 2016 09:44

Gisteren nog eens ingestapt in Biolase (1000 stuks aan $1,53), de afgelopen jaren heb ik hier 2 mooie ritjes gemaakt met respectievelijk 300% en 200% winst, hopelijk nu terug.

Financieel zijn ze even terug gesteld na hun kapitaalronde van 10 miljoen dollar begin augustus.
Biolase ($0.44)
Senomyx ($1.33)
Thrombogenics (€3,32)

Coins: Digibyte, Dogecoin, Reddcoin, Verge & Ripple.

Stefan
Forum actieveling
Forum actieveling
Berichten: 475
Lid geworden op: 18 Dec 2012 18:52
Likes: 53
Contact:

Re: Biolase

Berichtdoor Stefan » 20 Dec 2017 09:48

Biolase (BIOL) staat op het laagste punt ooit, hebben weer cash in handen en kunnen de focus weer leggen op de business,...


BIOLASE Announces Expiration of Rights Offering
Company Estimates It Will Receive Aggregate Gross Proceeds from Rights Offering of Approximately $12.0 Million

November 30, 2017 08:00 AM Eastern Standard Time

IRVINE, Calif.--(BUSINESS WIRE)--BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the subscription period for its previously announced rights offering to holders of shares of its common stock expired at 5:00 p.m., Eastern Time, on November 29, 2017, and these rights are no longer exercisable.

The Company received basic subscriptions and over-subscriptions for a total of 26,307,719 shares, exceeding the 26,302,703 shares offered in the rights offering. Available shares will be distributed proportionately among rights holders who exercised their over-subscription privilege based on the number of shares each rights holder subscribed for under the basic subscription right. Based on the review of results provided by the Company’s subscription agent, Computershare, Inc., the Company estimates that it will receive aggregate gross proceeds from the rights offering of approximately $12.0 million. The results of the rights offering and the Company’s estimates regarding the aggregate gross proceeds of the rights offering to be received by the Company are preliminary and subject to finalization and verification by its subscription agent.

The Company expects the subscription agent to distribute the shares and the sale proceeds during the week of December 4th.

https://www.businesswire.com/news/home/ ... s-Offering
Biolase ($0.44)
Senomyx ($1.33)
Thrombogenics (€3,32)

Coins: Digibyte, Dogecoin, Reddcoin, Verge & Ripple.